DCOY — Decoy Therapeutics Share Price
0.000.00%
Last trade - 00:00- $4.35m
- -$0.46m
- 20
- 39
- 16
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.02 | ||
| Price to Tang. Book | 1.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -119.31% | ||
| Return on Equity | -139.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.23 | 1.84 | n/a | n/a | n/a | n/a | 11.88 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Directors
- William McVicar CHM (63)
- David Arthur PRE (58)
- Mark Rosenblum CFO (67)
- Nadeem Mirza SVP
- Paul Lammers LED (63)
- Bruce Mccreedy DRC (61)
- Tess Burleson IND (54)
- Arnold Hanish IND (73)
- Jonathan Lieber IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- February 26th, 2014
- Public Since
- January 29th, 2015
- No. of Shareholders
- 139
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,384,177
- Address
- 2450 Holcombe Blvd Ste J-608, HOUSTON, 77021-2041
- Web
- https://salariuspharma.com/
- Phone
- +1 6178741821
- Contact
- Maureen McEnroe
- Auditors
- Ernst & Young LLP
Upcoming Events for DCOY
Q1 2026 Salarius Pharmaceuticals Inc Earnings Release
Q2 2026 Salarius Pharmaceuticals Inc Earnings Release
Similar to DCOY
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Decoy Therapeutics share price?
As of Today at 19:13 UTC, shares in Decoy Therapeutics are trading at $0.68. This share price information is delayed by 15 minutes.
How has the Decoy Therapeutics share price performed this year?
Shares in Decoy Therapeutics last closed at $0.68 and the price had moved by -95.94% over the past 365 days. In terms of relative price strength the Decoy Therapeutics share price has underperformed the S&P500 Index by -96.52% over the past year.
What are the analyst and broker recommendations for Decoy Therapeutics?
The overall consensus recommendation for Decoy Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Decoy Therapeutics dividend yield?
Decoy Therapeutics does not currently pay a dividend.
Does Decoy Therapeutics pay a dividend?
Decoy Therapeutics does not currently pay a dividend.
When does Decoy Therapeutics next pay dividends?
Decoy Therapeutics does not currently pay a dividend.
How do I buy Decoy Therapeutics shares?
To buy shares in Decoy Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Decoy Therapeutics?
As of the previous close price of $0.68, shares in Decoy Therapeutics had a market capitalisation of $4.35m.
Where are Decoy Therapeutics shares listed?
Here are the trading details for Decoy Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DCOY
What kind of share is Decoy Therapeutics?
Based on an overall assessment of its quality, value and momentum Decoy Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Decoy Therapeutics share price forecast for 2026?
The analyst consensus target price for shares in Decoy Therapeutics is $2.50. That is 267.11% above the last closing price of $0.68.
Analysts covering Decoy Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$9.17 for the next financial year.
Find out moreWhat is the trend in the Decoy Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Decoy Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -89.06%.
As of the last closing price of $0.68, shares in Decoy Therapeutics were trading -87.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Decoy Therapeutics PE Ratio?
The Decoy Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.68.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Decoy Therapeutics?
Decoy Therapeutics' management team is headed by:
- William McVicar - CHM
- David Arthur - PRE
- Mark Rosenblum - CFO
- Nadeem Mirza - SVP
- Paul Lammers - LED
- Bruce Mccreedy - DRC
- Tess Burleson - IND
- Arnold Hanish - IND
- Jonathan Lieber - IND